Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01769248 · ClinicalTrials.gov registry record · NA

Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle

A NA study of Pancreatic Cancer and Gastrointestinal Stromal Tumor, sponsored by Northwestern University.

Completed
Registry status
NA
Development phase
140
Enrollment target
3
Study locations

NCT01769248: Completed NA study of Pancreatic Cancer and Gastrointestinal Stromal Tumor, sponsored by Northwestern University.

NCT01769248 is a NA study of Pancreatic Cancer and Gastrointestinal Stromal Tumor that has completed, run by Northwestern University. The registered enrollment target is 140 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (64% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01769248, a NA study of Pancreatic Cancer and Gastrointestinal Stromal Tumor, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
NA
Development phase
140 participants
Enrollment target
3
Study locations

Study Summary

Endoscopic ultrasound (EUS) is paramount in the diagnosis and evaluation of cancers involving the gastrointestinal tract. EUS allows for the acquisition of cellular (fine needle aspirate - FNA) or tissue biopsy (fine needle biopsy - FNB) for diagnostic purposes. This has traditionally been done with fine needle aspirate where a needle is inserted into the tumor and potentially malignant cells are extracted for microscopic analysis. More recently, a needle that allows a tissue biopsy for histologic analysis has been FDA approved. The Echotip Procore (Cook Medical) core biopsy needle (ETP), has been demonstrated to provide excellent efficacy for core biopsy samples. Final diagnostic yield using this needle ranges from 80-90% and appears to be significantly greater than EUS-FNA for lesions requiring histology for diagnosis. However, there is currently only limited data from prospective studies comparing EUS-FNA to EUS-FNB with the ETP needle. The investigators propose a randomized, prospective, cross-over study comparing diagnostic accuracy of EUS-FNA to EUS-FNB.

Primary Outcome

The investigators' primary outcome measure will assess the diagnostic yield (percentage of patients with a diagnosis) of EUS-FNB (fine-needle biopsy) to provide a final diagnosis of the lesion being sampled. This will be expressed as a percentage.

Interventions

  • DEVICE Fine needle aspiration
  • DEVICE Fine needle biopsy

Study Locations (3)

California

  • UCLA Medical Center - Los Angeles
  • California Pacific Medical Center - San Francisco

Florida

  • Moffit Cancer Center - Tampa

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2012-09
Est. Completion 2014-02
Phase NA
Northwestern University

1,209 total trials

What the finished NCT01769248 record still lists

NCT01769248 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (64% lower).

The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fine needle aspiration is the first listed.

NCT01769248 reports a single indexed study location in California, Florida.

Frequently Asked Questions

What is clinical trial NCT01769248 about?

NCT01769248 is a clinical study titled "Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle". Endoscopic ultrasound (EUS) is paramount in the diagnosis and evaluation of cancers involving the gastrointestinal tract. EUS allows for the acquisition of cellular (fine needle aspirate - FNA) or tissue biopsy (fine needle biopsy - FNB) for diagnostic purposes. This has traditionally been done with...

What is the current status of trial NCT01769248?

This trial is currently completed. It is a NA study. The enrollment target is 140 participants. The study started on 2012-09. Estimated completion is 2014-02.

What conditions does trial NCT01769248 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Gastrointestinal Stromal Tumor, Lymphadenopathy.

What interventions are being tested in trial NCT01769248?

The interventions under investigation include: Fine needle aspiration (DEVICE), Fine needle biopsy (DEVICE).

Who is sponsoring clinical trial NCT01769248?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01769248 being conducted?

This trial has 3 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01769248's enrollment target sits among peer trials

140 82nd of 278 higher than 196 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01419561 · 140 participants · Phase 2

    Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

  • NCT01624805 · 140 participants · Phase 2

    Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

  • NCT02369770 · 140 participants · NA

    Sensory-Motor Rehabilitation Post Stroke

  • NCT02455193 · 140 participants · NA

    Neuronal Effects of Exercise in Schizophrenia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01769248, the US trial registry maintained by the National Library of Medicine. NCT01769248 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.